Applications of Positron Emission Tomography in the Development of Molecular Targeted Cancer Therapeutics

BioDrugs

Volumn 17, Issue 5, 2003, Pages 339-354

  Solomon, Benjamin ^a   McArthur, Grant A ^a   Cullinane, Carleen ^a   Zalcberg, John R ^a   Hicks, Rodney J ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID C 11; ANTINEOPLASTIC AGENT; BROMINE; CARBON 11; CELL RECEPTOR; COMBRETASTATIN A4; COPPER 64; DEOXYGLUCOSE; ENDOSTATIN; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GALLIUM; GALLIUM 68; IMATINIB; IODINE 123; IODINE 124; IRON 52; METHIONINE C 11; MONOCLONAL ANTIBODY; NITROGEN 15; OXYGEN 15; RADIOLIGAND; RUBIDIUM 82; TECHNETIUM 99M; THALLIUM 201; TOSITUMOMAB; TRACER; UNINDEXED DRUG; YTTRIUM;

AMINO ACID METABOLISM; AMINO ACID TRANSPORT; ANTIBODY LABELING; APOPTOSIS; BONE METABOLISM; CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MODEL; CANCER RADIOTHERAPY; CANCER THERAPY; CELL HYPOXIA; CELL METABOLISM; CELL PROLIFERATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DOSE CALCULATION; DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG LABELING; DRUG RESPONSE; DRUG TARGETING; ECHOGRAPHY; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GLUCOSE UTILIZATION; HUMAN; IMAGE QUALITY; IN VIVO STUDY; ISOTOPE LABELING; LIPID METABOLISM; LYMPHOMA; MEDICAL PARAMETERS; MEDICAL TECHNOLOGY; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MEDICINE; PHARMACODYNAMICS; PHARMACOKINETICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT OUTCOME; TUMOR BLOOD FLOW; VALIDATION PROCESS;

ANIMALS; DISEASE PROGRESSION; HUMANS; MODELS, ANIMAL; NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0142027639     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200317050-00004     Document Type: Review

References (158)

1. Gambhir SS, Czernin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001; 42 (5 Suppl.): 1S-93S
2. MacManus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003; 21 (7): 1285-92
3. Hara T, Inagaki K, Kosaka N, et al. Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET. J Nucl Med 2000; 41 (9): 1507-13
4. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998; 39 (6): 990-5
5. Hara T, Kosaka N, Shinoura N, et al. PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med 1997; 38 (6): 842-7
6. Hara T, Kosaka N, Kishi H. Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002; 43 (2): 187-99
7. DeGrado TR, Baldwin SW, Wang S, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001; 42 (12): 1805-14
8. Shreve P, Chiao PC, Humes HD, et al. Carbon-11-acetate PET imaging in renal disease. J Nucl Med 1995; 36 (9): 1595-601
9. Kubota K, Ito M, Fukuda H, et al. Cancer diagnosis with positron computed tomography and carbon-11-labelled L-methionine [letter]. Lancet 1983; II (8360): 1192
10. Bolster JM, Vaalburg W, Paans AM, et al. Carbon-11 labelled tyrosine to study tumor metabolism by positron emission tomography (PET). Eur J Nucl Med 1986; 12(7): 321-4
11. Weber WA, Wester HJ, Grosu AL, et al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 2000; 27 (5): 542-9
12. Inoue T, Tomiyoshi K, Higuichi T, et al. Biodistribution studies on L-3-[fluorine-18]fluoro-alpha-methyl tyrosine: a potential tumor-detecting agent. J Nucl Med 1998; 39 (4): 663-7
13. Kubota K, Ishiwata K, Kubota R, et al. Feasibility of fluorine-18-fluorophenylalanine for tumor imaging compared with carbon-11-L-methionine. J Nucl Med 1996; 37 (2): 320-5
14. Wienhard K, Herholz K, Coenen HH, et al. Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine. J Nucl Med 1991; 32 (7): 1338-46
15. Shields AF, Lim K, Grierson J, et al. Utilization of labeled thymidine in DNA synthesis: studies for PET. J Nucl Med 1990; 31 (3): 337-42
16. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998; 4(11): 1334-6
17. Conti PS, Alauddin MM, Fissekis JR, et al. Synthesis of 2′-fluoro-5-[11C]-methyl-1-beta-D-arabinofuranosyluracil ([11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. Nucl Med Biol 1995; 22 (6): 783-9
18. Blasberg RG, Roelcke U, Weinreich R, et al. Imaging brain tumor proliferative activity with [124I]iododeoxyuridine. Cancer Res 2000; 60 (3): 624-35
19. Glaser M, Collingridge DR, Aboagye EO, et al. Iodine-124 labelled annexin-V as a potential radiotracer to study apoptosis using positron emission tomography. Appl Radiat Isot 2003; 58 (1): 55-62
20. Zijlstra S, Gunawan J, Burchert W. Synthesis and evaluation of a 18F-labelled recombinant annexin-V derivative, for identification and quantification of apoptotic cells with PET. Appl Radiat Isot 2003; 58 (2): 201-7
21. Wilson CB, Lammertsma AA, McKenzie CG, et al. Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res 1992; 52(6): 1592-7
22. Ito M, Lammertsma AA, Wise RJ, et al. Measurement of regional cerebral blood flow and oxygen utilisation in patients with cerebral tumours using 150 and positron emission tomography: analytical techniques and preliminary results. Neuroradiology 1982; 23 (2): 63-74
23. Rasey JS, Koh WJ, Grierson JR, et al. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989; 17 (5): 985-91
24. Fujibayashi Y, Taniuchi H, Yonekura Y, et al. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997; 38 (7): 1155-60
25. Chapman JD, Schneider RF, Urbain JL, et al. Single-photon emission computed tomography and positron-emission tomography assays for tissue oxygenation. Semin Radiat Oncol 2001; 11 (1): 47-57
26. Sorger D, Patt M, Kumar P, et al. [18F]fluoroazomycinarabinofuranoside ([18]FAZA) and [18F]fluoromisonidazole ([18]FMISO): a comparative study of their selective uptake in hypoxic cells and PET imaging in experimental rat tumors. Nucl Med Biol 2003; 30 (3): 317-26
27. Schirrmeister H, Guhlmann A, Elsner K, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med 1999; 40 (10): 1623-9
28. Woodward GE, Hudson MT. The effect of 2-deoxy-D-glucose in glycolysis and respiration of tumor and normal tissues. Cancer Res 1954; 14: 599-605
29. Sokoloff L, Reivich M, Kennedy C, et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977; 28(5); 897-916
30. Gallagher BM, Ansari A, Atkins H, et al. Radiopharmaceuticals XXVII: 18F-labeled 2-deoxy-2-fluoro-D-glucose as a radiopharmaceutical for measuring regional myocardial glucose metabolism in vivo: tissue distribution and imaging studies in animals. J Nucl Med 1977; 18 (10): 990-6
31. Harris AL. Hypoxia: a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2 (1): 38-47
32. Warburg O, Pofner K, Negelein E. The metabolism of the cancer cell. Smith R, editor. The metabolism of tumors. New York: Richard Smith, 1931: 129-69
33. Semenza GL, Roth PH, Fang HM, et al. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994; 269 (38): 23757-63
34. Osthus RC, Shim H, Kim S, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000; 275 (29): 21797-800
35. Ahuja V, Coleman RE, Herndon J, et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998; 83 (5): 918-24
36. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on 18F-fluoro-2-deoxy-glucose: positron emission tomography scan in non-small-cell lung cancer, an analysis of 125 cases. J Clin Oncol 1999; 17 (10); 3201-6
37. Higashi K, Ueda Y, Arisaka Y, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small-cell lung cancer. J Nucl Med 2002; 43 (1): 39-45
38. Nakata B, Chung YS, Nishimura S, et al. 18F-fluorodeoxyglucose positron emission tomography and the prognosis of patients with pancreatic adenocarcinoma. Cancer 1997; 79 (4): 695-9
39. Allal AS, Dulguerov P, Allaoua M, et al. Standardized uptake value of 2-[18F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 2002; 20 (5): 1398-404
40. Franzius C, Bielack S, Flege S, et al. Prognostic significance of 18F-FDG and 99mTc-methylene diphosphonate uptake in primary osteosarcoma. J Nucl Med 2002; 43 (8): 1012-7
41. Czernin J, Phelps ME. Positron emission tomography scanning: current and future applications. Annu Rev Med 2002; 53: 89-112
42. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981; 47 (1): 207-14
43. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92 (3): 205-16
44. Price P, Jones T. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy?: the EC PET Oncology Concerted Action and the EORTC PET Study Group. Eur J Cancer 1995; 31A (12): 1924-7
45. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347 (7): 472-80
46. Van den Abbeele AD, Badawi RD, Cliche J-P, et al. 18F-FDG-PET predicts response to imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol 2002; 21: 403a
47. Van Oosterom AT, Judson I, Verweij J, et al. STI 571, an active drug in metastatic gastro intestinal stromal tumors (GIST), an EORTC phase I study. Proc Am Soc Clin Oncol 2001; 20: 1a
48. Blanke CD, von Mehren M, Joensuu H, et al. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients (pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing C-KIT (CD117). Proc Am Soc Clin Oncol 2001; 20: 1a
49. Kostakoglu L, Leonard JP, Coleman M, et al. Prediction of response to therapy using early F-18 fluorodeoxyglucose imaging (FDG-PET) in patients undergoing I-131 tositumomab therapy. Proc Am Soc Clin Oncol 2001; 20: 237b
50. Flamen P, Van Cutsem E, Lerut A, et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002; 13 (3): 361-8
51. Spence AM, Muzi M, Graham MM, et al. 2-[18F]fluoro-2-deoxyglucose and glucose uptake in malignant gliomas before and after radiotherapy: correlation with outcome. Clin Cancer Res 2002; 8 (4): 971-9
52. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed 1992; 5 (5): 303-24
53. Katz-Brull R, Seger D, Rivenson-Segal D, et al. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res 2002; 62 (7): 1966-70
54. Katz-Brull R, Degani H. Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res 1996; 16(3B): 1375-80
55. Katz-Brull R, Margalit R, Bendel P, et al. Choline metabolism in breast cancer; 2H-, 13C-and 31P-NMR studies of cells and tumors. MAGMA 1998; 6(1): 44-52
56. Kobori O, Kirihara Y, Kosaka N, et al. Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose: a novel method of preoperative lymph node staging. Cancer 1999; 86 (9): 1638-48
57. DeGrado TR, Coleman RE, Wang S, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001; 61 (1): 110-7
58. Price DT, Coleman RE, Liao RP, et al. Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002; 168 (1): 273-80
59. Cuadrado A, Carnero A, Dolfi F, et al. Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene 1993; 8 (11): 2959-68
60. Ronen SM, Jackson LE, Beloueche M, et al. Magnetic resonance detects changes in phosphocholine associated with Ras activation and inhibition in N1H 3T3 cells. Br J Cancer 2001; 84 (5): 691-6
61. Liu D, Hutchinson OC, Osman S, et al. Use of radiolabelled choline as a pharmacodynamic marker for the signal transduction inhibitor geldanamycin. Br J Cancer 2002; 87 (7): 783-9
62. Yoshimoto M, Waki A, Yonekura Y, et al. Characterization of acetate metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 2001; 28 (2): 117-22
63. Oyama N, Akino H, Kanamaru H, et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002; 43 (2): 181-6
64. Kotzerke J, Volkmer BG, Neumaier B, et al. Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2002; 29(10): 1380-4
65. Isselbacher KJ. Sugar and amino acid transport by cells in culture: differences between normal and malignant cells. N Engl J Med 1972; 286 (17): 929-33
66. Ishiwata K, Hatazawa J, Kubota K, et al. Metabolic fate of L-[methyl-11C]methionine in human plasma. Eur J Nucl Med 1989; 15 (10): 665-9
67. Jager PL, Vaalburg W, Pruim J, et al. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med 2001; 42 (3): 432-45
68. Goldman S, Levivier M, Pirotte B, et al. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 1997; 38 (9): 1459-62
69. Nuutinen J, Sonninen P, Lehikoinen P, et al. Radiotherapy treatment planning and long-term follow-up with [11C]methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys 2000; 48 (1): 43-52
70. Heiss P, Mayer S, Herz M, et al. Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. J Nucl Med 1999; 40 (8): 1367-73
71. Wester HJ, Herz M, Weber W, et al. Synthesis and radiopharmacology of O-(2-[18F]fluoroethyl)-L-tyrosine for tumor imaging. J Nucl Med 1999; 40 (1): 205-12
72. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100 (1): 57-70
73. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem 1988; 263 (17): 8350-8
74. Hengstschlager M, Knofler M, Mullner EW, et al. Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells. J Biol Chem 1994; 269 (19): 13836-42
75. Wells P, Gunn RN, Alison M, et al. Assessment of proliferation in vivo using 2-[11C]thymidine positron emission tomography in advanced intra-abdominal malignancies. Cancer Res 2002; 62 (20): 5698-702
76. Shields AF, Mankoff DA, Link JM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med 1998; 39 (10): 1757-62
77. Rasey JS, Grierson JR, Wiens LW, et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002; 43 (9): 1210-7
78. Buck AK, Schirrmeister H, Hetzel M, et al. 3-deoxy-3-[18F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002; 62 (12): 3331-4
79. Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3′deoxy-3′-[18F]fluorothymidine ([18F]FLT) as a proliferation imaging tracer in humans: correlation of [18F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002; 8 (11): 3315-23
80. Fadok VA, Voelker DR, Campbell PA, et al. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992; 148 (7): 2207-16
81. Hofstra L, Liem IH, Dumont EA, et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 2000; 356 (9225); 209-12
82. Blankenberg FG, Naumovski L, Tait JF, et al. Imaging cyclophosphamide-induced intramedullary apoptosis in rats using 99mTc-radiolabeled annexin V. J Nucl Med 2001; 42 (2): 309-16
83. Mochizuki T, Kuge Y, Zhao S, et al. Detection of apoptotic tumor response in vivo after a single dose of chemotherapy with (99m)Tc-annexin V. J Nucl Med 2003; 44(1): 92-7
84. Belhocine T, Steinmetz N, Hustinx R, et al. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002; 8 (9): 2766-74
85. Anderson H, Price P. Clinical measurement of blood flow in tumours using positron emission tomography: a review. Nucl Med Commun 2002; 23 (2): 131-8
86. Lammertsma AA, Wise RJ, Cox TC, et al. Measurement of blood flow, oxygen utilisation, oxygen extraction ratio, and fractional blood volume in human brain tumours and surrounding oedematous tissue. Br J Radiol 1985; 58 (692): 725-34
87. Beaney RP, Lammertsma AA, Jones T, et al. Positron emission tomography for in-vivo measurement of regional blood flow, oxygen utilisation, and blood volume in patients with breast carcinoma. Lancet 1984; I (8369): 131-4
88. Mineura K, Sasajima T, Itoh Y, et al. Blood flow and metabolism of central neurocytoma: a positron emission tomography study. Cancer 1995; 76 (7): 1224-32
89. Yamaguchi A, Taniguchi H, Kunishima S, et al. Correlation between angiographically assessed vascularity and blood flow in hepatic metastases in patients with colorectal carcinoma. Cancer 2000; 89 (6): 1236-44
90. Anderson H, Japp J, Price P. Measurement of tumour and normal tissue (NT) perfusion by positron emission tomography (PET) in the evaluation of antivascular therapy: results in the phase I study of combretastatin A4 phosphate (CA4P). Proc Am Soc Clin Oncol 2000; 19: 695
91. Herbst RS, Mullani NA, Davis DW, et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 2002; 20 (18): 3804-14
92. Herbst RS, Hess KR, Tran HT, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002; 20 (18): 3792-803
93. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001; 93 (4): 266-76
94. Gray LH, Conger AD, Ebert M, et al. Concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26: 638-48
95. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994; 13 (2): 139-68
96. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 2000; 6 (4): 157-62
97. Kennedy AS, Raleigh JA, Perez GM, et al. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int J Radiat Oncol Biol Phys 1997; 37 (4): 897-905
98. Lord EM, Harwell L, Koch CJ. Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts. Cancer Res 1993; 53 (23): 5721-6
99. Koh WJ, Rasey JS, Evans ML, et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992; 22 (1): 199-212
100. Rasey JS, Wui-Jin K, Evans ML, et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996; 36(2): 417-28
101. Koh WJ, Bergman KS, Rasey JS, et al. Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 1995; 33(2): 391-8
102. Rischin D, Peters L, Hicks R, et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19 (2): 535-42
103. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995; 22(3): 265-80
104. Lewis JS, Welch MJ. PET imaging of hypoxia. Q J Nucl Med 2001; 45 (2): 183-8
105. Engelhardt EL, Schneider RF, Seeholzer SH, et al. The synthesis and radiolabeling of 2-nitroimidazole derivatives of cyclam and their preclinical evaluation as positive markers of tumor hypoxia. J Nucl Med 2002; 43 (6): 837-50
106. Dehdashti F, Grigsby PW, Mintun MA, et al. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 6OCu-ATSM: relationship to therapeutic response, a preliminary report. Int J Radiat Oncol Biol Phys 2003; 55 (5): 1233-8
107. Dehdashti F, Mintun MA, Lewis JS, et al. In vivo assessment of tumor hypoxia in lung cancer with (6O)Cu-ATSM. Eur J Nucl Med Mol Imaging 2003; 30 (6): 844-50
108. Chao KSC, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2001; 49 (4): 1171-82
109. Bakir MA, Eccles S, Babich JW, et al. c-erbB2 protein overexpression in breast cancer as a target for PET using iodine-124-labeled monoclonal antibodies. J Nucl Med 1992; 33 (12): 2154-60
110. Divgi CR, Welt S, Kris M, et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst 1991; 83 (2): 97-104
111. Ramos-Suzarte M, Rodriguez N, Oliva JP, et al. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin. Part III: clinical trials safety and diagnostic efficacy. J Nucl Med 1999; 40 (5): 768-75
112. Jayson GC, Zweit J, Jackson A, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002; 94 (19): 1484-93
113. Collingridge DR, Carroll VA, Glaser M, et al. The development of [124I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res 2002; 62 (20): 5912-9
114. Wu AM, Yazaki PJ, Tsai S, et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A 2000; 97 (15): 8495-500
115. Behr TM, Gotthardt M, Barth A, et al. Imaging tumors with peptide-based radioligands. Q J Nucl Med 2001; 45 (2): 189-200
116. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe 1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20 (8): 716-31
117. Anderson CJ, Dehdashti F, Cutler PD, et al. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 2001; 42 (2): 213-21
118. Henze M, Schuhmacher J, Hipp P, et al. PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas. J Nucl Med 2001; 42 (7): 1053-6
119. Wester HJ, Schottelius M, Scheidhauer K, et al. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide. Eur J Nucl Med Mol Imaging 2003; 30 (1): 117-22
120. Mintun MA, Welch MJ, Siegel BA, et al. Breast cancer: PET imaging of estrogen receptors. Radiology 1988; 169 (1): 45-8
121. Mortimer JE, Dehdashti F, Siegel BA, et al. Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 1996; 2 (6): 933-9
122. Dehdashti F, Flanagan FL, Mortimer JE, et al. Positron emission tomographic assessment of 'metabolic flare' to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999; 26 (1): 51-6
123. Verhagen A, Studeny M, Luurtsema G, et al. Metabolism of a [18F]fluorine labeled progestin (21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone) in humans: a clue for future investigations. Nucl Med Biol 1994; 21 (7); 941-52
124. Dehdashti F, McGuire AH, Van Brocklin HF, et al. Assessment of 21-[18F]fluoro16 alpha-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas. J Nucl Med 1991; 32 (8): 1532-7
125. Dence CS, John CS, Bowen WD, et al. Synthesis and evaluation of 18F-labeled benzamides: high affinity sigma receptor ligands for PET imaging. Nucl Med Biol 1997; 24 (4): 333-40
126. Waterhouse RN, Mardon K, Giles KM, et al. Halogenated 4-(phenoxymethyl)piperidines as potential radiolabeled probes for sigma-1 receptors: in vivo evaluation of [123I]-1-(iodopropen-2-y1)-4-[(4-cyanophenoxy)methyl]piperidine. J Med Chem 1997; 40 (11): 1657-67
127. Mach RH, Huang Y, Buchheimer N, et al. [18F]N-(4′ -fluorobenzyl)-4-(3-bromophenyl) acetamide for imaging the sigma receptor status of tumors: comparison with [18F]FDG, and [125I]IUDR. Nucl Med Biol 2001; 28 (4): 451-8
128. Arap W, Kolonin MG, Trepel M, et al. Steps toward mapping the human vasculature by phage display. Nat Med 2002; 8 (2): 121-7
129. Tavitian B, Terrazzino S, Kuhnast B, et al. In vivo imaging of oligonucleotides with positron emission tomography. Nat Med 1998; 4 (4): 467-71
130. Dewanjee MK, Ghafouripour AK, Kapadvanjwala M, et al. Noninvasive imaging of c-Myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model. J Nucl Med 1994; 35 (6): 1054-63
131. Younes CK, Boisgard R, Tavitian B. Labelled oligonucleotides as radiopharmaceuticals: pitfalls, problems and perspectives. Curr Pharm Des 2002; 8 (16): 1451-66
132. Cerchia L, Hamm J, Libri D, et al. Nucleic acid aptamers in cancer medicine. FEBS Lett 2002; 528 (1-3): 12-6
133. Harte RJA, Matthews JC, O'Reilly SM, et al. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. J Clin Oncol 1999; 17 (5): 1580-9
134. Saleem A, Yap J, Osman S, et al. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet 2000; 355 (9221): 2125-31
135. Moehler M, Dimitrakopoulou-Strauss A, Gutzler F, et al. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer 1998; 83 (2): 245-53
136. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, et al. Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med 1998; 39 (7): 1197-202
137. Inoue T, Kim EE, Wallace S, et al. Positron emission tomography using [18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother Radiopharm 1996; 11 (4): 235-45
138. Inoue T, Kim EE, Wallace S, et al. Preliminary study of cardiac accumulation of F-18 fluorotamoxifen in patients with breast cancer. Clin Imaging 1997; 21 (5): 332-6
139. Meikle SR, Matthews JC, Brock CS, et al. Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. Cancer Chemother Pharmacol 1998; 42 (3): 183-93
140. Saleem A, Brown GD, Brady F, et al. Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 2003; 63 (10): 2409-15
141. Hendrikse NH, Franssen EJ, van der Graaf WT, et al. Visualization of multidrug resistance in vivo. Eur J Nucl Med 1999; 26 (3): 283-93
142. Saleem A, Harte RJ, Matthews JC, et al. Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography. J Clin Oncol 2001; 19 (5): 1421-9
143. Tjuvajev JG, Stockhammer G, Desai R, et al. Imaging the expression of transfected genes in vivo. Cancer Res 1995; 55 (24): 6126-32
144. Gambhir SS, Bauer E, Black ME, et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc Natl Acad Sci U S A 2000; 97 (6): 2785-90
145. MacLaren DC, Gambhir SS, Satyamurthy N, et al. Repetitive, non-invasive imaging of the dopamine D2 receptor as a reporter gene in living animals. Gene Ther 1999; 6 (5): 785-91
146. Liang Q, Satyamurthy N, Barrio JR, et al. Noninvasive, quantitative imaging in living animals of a mutant dopamine D2 receptor reporter gene in which ligand binding is uncoupled from signal transduction. Gene Ther 2001; 8 (19): 1490-8
147. Doubrovin M, Ponomarev V, Beresten T, et al. Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci U S A 2001; 98 (16): 9300-5
148. Ponomarev V, Doubrovin M, Lyddane C, et al. Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo. Neoplasia 2001; 3 (6): 480-8
149. Weissleder R, Mahmood U. Molecular imaging. Radiology 2001; 219 (2): 316-33
150. Del Guerra A, Belcari N. Advances in animal PET scanners. Q J Nucl Med 2002; 46 (1): 35-47
151. Lewis JS, Achilefu S, Garbow JR, et al. Small animal imaging: current technology and perspectives for oncological imaging. Eur J Cancer 2002; 38 (16): 2173-88
152. Van Dyke T, Jacks T. Cancer modeling in the modern era: progress and challenges. Cell 2002; 108 (2): 135-44
153. Haubner R, Wester HJ, Weber WA, et al. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res 2001; 61 (5): 1781-5
154. Betensky RA, Louis DN, Cairncross JG. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 2002; 20 (10): 2495-9
155. Gelmon KA, Eisenhauer EA, Harris AL, et al. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst 1999; 91 (15): 1281-7
156. Fox E, Curt GA, Balls FM. Clinical trial design for target-based therapy. Oncologist 2002; 7 (5): 401-9
157. Korn EL, Arbuck SG, Pluda JM, et al. Clinical trial designs for cytostatic agents: are new approaches needed? J Clin Oncol 2001; 19 (1): 265-72
158. Hoffman JM. Imaging in cancer: a National Cancer Institute 'extraordinary opportunity'. Neoplasia 2000; 2 (1-2): 5-8